Clinical trial
Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial
NCT03187795 is registered in ClinicalTrials.gov with Kessler Foundation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial
- Lead sponsor
- Kessler Foundation
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- April 3, 2019
- Completion date
- March 30, 2022
- Enrollment
- 62 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.